Shares of Biogen, a US biotech company, trade around 50% higher in premarket today. Shares rally following results of an Alzheimer drug (Lecanemab) trial that Biogen developed along with Eisai, Japanese pharmaceutical company. Results showed that the pace of cognitive decline in patients who received Lecanemab dropped by 27% over 18 months compared to patients who received placebo. This is massive as it is the first drug to show effectiveness against Alzheimer in a definitive, large-scale trial. While the company noted that some side effects occurred, it also said that they were rarely severe.
Biogen trades around 50% higher in premarket today. Weekly chart. Source: xStation5
Morning Wrap: OpenAI Revenue Concerns Weigh on Wall Street
Is Starbucks eyeing Chipotle❓ The market reacts nervously to the FT's reports of a takeover🔥
Stock of the Week: Marvell Technology and the Race for AI Infrastructure’s Most Valuable Resource
Market Wrap: A 4% surge in oil prices weighs on indices (08.10.2026)